IBP Stock +106.23% Since Nov ’07 Pick IBP Stock +106.23% Since Nov ’07 Pick Unlock Top Buy Picks
Pfizer has faced numerous challenges, including a decline in COVID-19 vaccine demand and high costs, but the worst is likely priced into the stock. The company is focusing on innovation and has ambiti
Pfizer's PEG ratio according to one widely used financial website is shockingly low. This low valuation metric raises questions.

Pfizer: The Market Is Wrong

03:00pm, Thursday, 11'th Apr 2024
Over the last twelve months, Pfizer's stock experienced a massive sell-off due to a massive revenue and EPS drop after the COVID-related spikes of 2021 and 2022. However, the company's financial perfo
Pfizer (PFE) expects its operational revenues to improve, driven by its in-line products like Vyndaqel, new launches like Abrysvo and newly acquired products, including those acquired from Seagen.
With rising concerns in the market potentially forcing a strategic shift, investors may want to consider healthcare stocks. No matter what happens, people need access to health-related products and se
Pfizer's (PFE) RSV vaccine, Abrysvo, generates an immune response in a phase III study evaluating it in higher-risk adults aged 18 to 59, non-inferior to that in older adults.

Where Will Pfizer Stock Be in 10 Years?

02:06am, Wednesday, 10'th Apr 2024
Drug giant Pfizer has been investing big money into oncology in recent years. In a decade, the company's product mix may look significantly different than today.
A late-stage trial of Pfizer's RSV vaccine showed promising results in adults under 60 years old, suggesting the shot could help people as young as 18, the company announced Tuesday, amid an effort to
Pfizer Inc   (NYSE PFE) stock is up 1.7% at $27.04 at last check, following news a late-stage trial of its respiratory syncytial virus (RSV) vaccine Abrysvo generated an immune response in higher r
Pfizer plans to file for an expanded approval of Abrysvo, which is currently approved for adults ages 60 and above and expectant mothers.
The stock market's been wobbly in the past couple of weeks, influenced by Federal Reserve officials' cautious stance on cutting interest rates. However, with a cooling job market, it's only a matter o
Ken Griffin's Citadel hedge fund more than quadrupled its stake in this stock in 2023 Q4. Griffin probably likes the stock because of its valuation, dividend, and surprisingly robust growth prospects.
In the latest trading session, Pfizer (PFE) closed at $26.58, marking a -0.3% move from the previous day.

Is Trending Stock Pfizer Inc. (PFE) a Buy Now?

10:06am, Monday, 08'th Apr 2024
Pfizer (PFE) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Pfizer has had plenty of bad news, with more on the way. New products and acquisitions should help the drugmaker return to growth.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE